Results 131 to 140 of about 1,235,428 (322)
Molecular Oncology, EarlyView.Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice +16 more
wiley +1 more source
Linchuang shenzangbing zazhiObjectiveTo explore the diagnostic values of serum galactose-deficient IgA1（Gd-IgA1）， C4， complement factor H（CFH） and complement factor H-related protein （CFHRP） 1， 3， 5 in IgA nephropathy（IgAN）.MethodsA total of 58 patients with primary IgAN diagnosed ...
Zou Mei +4 more
doaj
Recombinant complement factor H in complement-mediated diseases
, 2022 Complement Factor H (FH) is a 155-kDa plasma glycoprotein that regulates the alternative pathway of the complement system. Mutations or deficiencies in FH are associated with some cases of the kidney diseases C3 glomerulopathy and atypical haemolytic uraemic syndrome (aHUS).
openaire +2 more sources
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
Molecular Oncology, EarlyView.This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
Data from Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103
, 2023 Ryan T. Bushey +5 more
openalex +1 more source
Retinal changes precede visual dysfunction in the complement factor h knockout mouse [PDF]
, 2013 We previously reported that aged mice lacking complement factor H (CFH) exhibit visual defects and structural changes in the retina. However, it is not known whether this phenotype is age-related or is the consequence of disturbed development. To address
Greenwood, J, Moss, SE, Williams, JA
core
ATF4‐mediated stress response as a therapeutic vulnerability in chordoma
Molecular Oncology, EarlyView.We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone +11 more
wiley +1 more source
Recognition of Malondialdehyde-modified Proteins by the C Terminus of Complement Factor H Is Mediated via the Polyanion Binding Site and Impaired by Mutations Found in Atypical Hemolytic Uremic Syndrome [PDF]
, 2013 Satu Hyvärinen +4 more
openalex +1 more source
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source
Localization of the complement-component-C3b-binding site and the cofactor activity for factor I in the 38kDa tryptic fragment of factor H [PDF]
, 1984 Jochem Alsenz +3 more
openalex +1 more source